ClinicalTrials.gg
CompletedNCT01115673Updated May 28, 2012Results posted

To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery

A Phase 3 interventional study of Acetaminophen and Placebo Control in Pain, sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.. Completed at 1 site in United States. Open to participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2012-05-28.

Sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
16 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
8th of 137
540 · median 95
Started
2010
with 5 others
Phase 3
22 of 137
none open now
Registered
35th of 137
by date

Among the 137 studies testing acetaminophen in Pain, this one is the 8th largest by enrollment, is one of 6 that started in 2010, is one of 22 in phase 3, and was the 35th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 16 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and efficacy of acetaminophen 650 mg and acetaminophen 1000 mg in dental surgery.

Read the detailed description

This trial is to assess the relative efficacy of acetaminophen 1000 mg versus acetaminophen 650 mg over a six-hour period, in subjects experiencing at least moderate post-operative dental pain.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
16 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be at least 16 and less than 51 years of age
  • Must weigh at least 100 lbs with a of at least 18 and less than 30
  • Must have up to four of their back teeth (third-molars) pulled

Exclusion criteria

Exclusion Criteria:

  • Cannot be allergic to acetaminophen (Tylenol)
  • Cannot be pregnant (or planning to be pregnant) or nursing a baby
  • Cannot have any other medical conditions that the investigator determines might compromise your safety or the study results
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
540 participants (actual)

Study arms

  • Experimental
    ACE-1000

    1000 mg Acetaminophen Caplet

    Drug: Acetaminophen

  • Active comparator
    ACE-650

    650 mg Acetaminophen Caplet

    Drug: Acetaminophen

  • Placebo comparator
    ACE-0

    0 mg Acetaminophen Caplet

    Drug: Placebo Control

Interventions

  • Acetaminophen Caplet - single dose

    Also known as: Tylenol

  • DrugPlacebo Control

    0 mg Caplet - single dose

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Overall Analgesic Efficacy - Sum of Pain Intensity Difference and Pain Relief Scores Over Six Hours (SPRID6)

    Weighted Sum of Pain Intensity Difference and Pain Relief Scores Over Six Hours (SPRID6) - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief. For SPRID6, the total possible minimum value is -300 (worst) and the total possible maximum value is 1200 (best). The weights used in the calculation of weighted sums were equal to the elapsed time (hour) between the time point of interest and the preceding time point.

    Time frame: 6 Hours

Secondary outcomes

  1. Sum of Pain Intensity Difference Over Six Hours (SPID6)

    Weighted Sum of the Pain Intensity Difference from Baseline Over Six Hours (SPID6) - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain. The total possible minimum value is -300 (worst) and the total possible maximum value is 600 (best). The weights used in the calculation of weighted sums were equal to the elapsed time (hour) between the time point of interest and the preceding time point.

    Time frame: 6 Hours

  2. Sum of Pain Relief Scores Over Six Hours (TOTPAR6)

    Weighted Sum of the Pain Relief Scores Over Six Hours (TOTPAR6) - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief. The total possible minimum value is 0 (worst) and the total possible maximum value is 600 (best). The weights used in the calculation of weighted sums were equal to the elapsed time (hour) between the time point of interest and the preceding time point.

    Time frame: 6 Hours

  3. Pain Intensity Difference (PID) at 15 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 15 Minutes

  4. Pain Intensity Difference (PID) at 30 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 30 Minutes

  5. Pain Intensity Difference (PID) at 45 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 45 Minutes

  6. Pain Intensity Difference (PID) at 60 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 60 Minutes

  7. Pain Intensity Difference (PID) at 75 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time Point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 75 Minutes

  8. Pain Intensity Difference (PID) at 90 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 90 Minutes

  9. Pain Intensity Difference (PID) at 120 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 120 Minutes

  10. Pain Intensity Difference (PID) at 180 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 180 Minutes

  11. Pain Intensity Difference (PID) at 240 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 240 Minutes

  12. Pain Intensity Difference (PID) at 300 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 300 Minutes

  13. Pain Intensity Difference (PID) at 360 Minutes

    Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

    Time frame: 360 Minutes

  14. Pain Relief (PAR) Scores at 15 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 15 Minutes

  15. Pain Relief (PAR) Scores at 30 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 30 Minutes

  16. Pain Relief (PAR) Scores at 45 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 45 Minutes

  17. Pain Relief (PAR) Scores at 60 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 60 Minutes

  18. Pain Relief (PAR) Scores at 75 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 75 Minutes

  19. Pain Relief (PAR) Scores at 90 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 90 Minutes

  20. Pain Relief (PAR) Scores at 120 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 120 Minutes

  21. Pain Relief (PAR) Scores at 180 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 180 Minutes

  22. Pain Relief (PAR) Scores at 240 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 240 Minutes

  23. Pain Relief (PAR) Scores at 300 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 300 Minutes

  24. Pain Relief (PAR) Scores at 360 Minutes

    Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

    Time frame: 360 Minutes

  25. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 15 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 15 Minutes

  26. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 30 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 30 Minutes

  27. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 45 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 45 Minutes

  28. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 60 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 60 Minutes

  29. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 75 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 75 Minutes

  30. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 90 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 90 Minutes

  31. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 120 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 120 Minutes

  32. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 180 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 180 Minutes

  33. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 240 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 240 Minutes

  34. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 300 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 300 Minutes

  35. Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 360 Minutes

    Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

    Time frame: 360 Minutes

  36. Time to Meaningful Pain Relief

    Minutes until meaningful pain relief was achieved. A stopwatch was provided to the subject after ingestion of the study medication. The subject was instructed to stop the stopwatch when the relief from the starting pain was meaningful to them.

    Time frame: within 6 Hours

  37. Time to Confirmed Perceptible Pain Relief

    Minutes until confirmed perceptible pain relief was achieved. A stopwatch was provided to the subject after ingestion of the study medication. The subject was instructed to stop the stopwatch when they first began to feel any pain relieving effect whatsoever of the drug, that was when they first felt any pain relief. It did not necessarily mean they felt completely better, although they might have, but when they first felt any difference in the pain.

    Time frame: within 6 Hours

  38. Duration of Analgesia - Time to Rescue

    Minutes until rescue medication was given.

    Time frame: within 6 Hours

  39. Rescue Rates Through Four Hours

    Percentage of subjects using rescue medication.

    Time frame: through 4 Hours

  40. Rescue Rates Through Six Hours

    Percentage of subjects using rescue medication.

    Time frame: through 6 Hours

  41. Percentage of Subjects With >50% of the Maximum Possible TOTPAR6 Score

    Percentage of Subjects with \>50% of the Maximum Possible TOTPAR6 Score - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 600 so \>50% is \>300 out of 600

    Time frame: 6 Hours

  42. Patient Global Evaluation

    Patient Assessment of the Pain Medication - Number of Subjects rating the medication they received as a pain reliever on a score of 0-4, where 0=poor, 1=fair, 2=good, 3=very good, 4=excellent

    Time frame: 6 Hours

07

Results

Posted May 28, 2012
Limitations and caveats
Analysis is based on the Intent-to-Treat (ITT) set, which included all subjects who were randomized, took study medication, did not vomit within 60 minutes after dosing, and had a baseline pain score and at least one post-randomization assessment.

Participant flow

Participant flow — Overall Study
MilestoneACE-1000ACE-650ACE-0
Started23924160
Completed23924160
Not completed000

Outcome measures

PrimaryOverall Analgesic Efficacy - Sum of Pain Intensity Difference and Pain Relief Scores Over Six Hours (SPRID6)

Weighted Sum of Pain Intensity Difference and Pain Relief Scores Over Six Hours (SPRID6) - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief. For SPRID6, the total possible minimum value is -300 (worst) and the total possible maximum value is 1200 (best). The weights used in the calculation of weighted sums were equal to the elapsed time (hour) between the time point of interest and the preceding time point.

Time frame:
6 Hours
Reported as:
Least squares mean · units on a scale
Overall Analgesic Efficacy - Sum of Pain Intensity Difference and Pain Relief Scores Over Six Hours (SPRID6)
units on a scaleACE-1000ACE-650ACE-0
Overall Analgesic Efficacy - Sum of Pain Intensity Difference and Pain Relief Scores Over Six Hours (SPRID6)529.4 ± 22.31427.3 ± 22.2160.0 ± 44.51
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 · Mean difference (final values): 469.37SPRID6 = 0.25 times (PRID at 15 min + PRID at 30 min + PRID at 45 min + PRID at 60 min + PRID at 75 min + PRID at 90 min) + 0.5 times (PRID at 120 minutes) + PRID at 3 hours + PRID at 4 hours + PRID at 5 hours + PRID at 6 hours.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.001 · Mean difference (final values): 102.09SPRID6 = 0.25 times (PRID at 15 min + PRID at 30 min + PRID at 45 min + PRID at 60 min + PRID at 75 min + PRID at 90 min) + 0.5 times (PRID at 120 minutes) + PRID at 3 hours + PRID at 4 hours + PRID at 5 hours + PRID at 6 hours.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 · Mean difference (final values): 367.28SPRID6 = 0.25 times (PRID at 15 min + PRID at 30 min + PRID at 45 min + PRID at 60 min + PRID at 75 min + PRID at 90 min) + 0.5 times (PRID at 120 minutes) + PRID at 3 hours + PRID at 4 hours + PRID at 5 hours + PRID at 6 hours.
SecondarySum of Pain Intensity Difference Over Six Hours (SPID6)

Weighted Sum of the Pain Intensity Difference from Baseline Over Six Hours (SPID6) - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain. The total possible minimum value is -300 (worst) and the total possible maximum value is 600 (best). The weights used in the calculation of weighted sums were equal to the elapsed time (hour) between the time point of interest and the preceding time point.

Time frame:
6 Hours
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference Over Six Hours (SPID6)
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference Over Six Hours (SPID6)222.5 ± 10.49174.3 ± 10.44-4.2 ± 20.93
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 226.70Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 48.14Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 178.56Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Relief Scores Over Six Hours (TOTPAR6)

Weighted Sum of the Pain Relief Scores Over Six Hours (TOTPAR6) - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief. The total possible minimum value is 0 (worst) and the total possible maximum value is 600 (best). The weights used in the calculation of weighted sums were equal to the elapsed time (hour) between the time point of interest and the preceding time point.

Time frame:
6 Hours
Reported as:
Least squares mean · units on a scale
Sum of Pain Relief Scores Over Six Hours (TOTPAR6)
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Relief Scores Over Six Hours (TOTPAR6)306.9 ± 12.02253.0 ± 11.9664.3 ± 23.98
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 242.67Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.002 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 53.95Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 188.72Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 15 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
15 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 15 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 15 Minutes5.6 ± 0.926.9 ± 0.911.3 ± 1.83
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = 0.037 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 4.30Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.294 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): -1.36Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = 0.006 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 5.66Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 30 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
30 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 30 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 30 Minutes21.3 ± 1.4821.5 ± 1.470.5 ± 2.95
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 20.85Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.946 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): -0.14Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 20.99Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 45 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
45 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 45 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 45 Minutes33.9 ± 1.7132.8 ± 1.710.2 ± 3.42
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 33.68Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.661 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 1.06Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 32.62Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 60 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
60 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 60 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 60 Minutes40.4 ± 1.8236.6 ± 1.81-0.1 ± 3.62
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 40.56Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.13 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 3.88Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 36.67Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 75 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time Point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
75 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 75 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 75 Minutes43.1 ± 1.8837.6 ± 1.87-0.9 ± 3.74
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 43.97Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.041 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 5.42Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 38.55Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 90 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
90 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 90 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 90 Minutes44.4 ± 1.9338.0 ± 1.92-0.6 ± 3.85
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 44.97Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.02 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 6.34Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 38.63Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 120 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
120 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 120 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 120 Minutes44.8 ± 2.0035.7 ± 1.99-2.7 ± 3.99
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 47.46Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 9.08Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 38.38Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 180 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
180 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 180 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 180 Minutes40.8 ± 2.0331.9 ± 2.02-2.6 ± 4.05
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 43.42Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.002 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 8.83Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 34.59Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 240 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
240 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 240 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 240 Minutes40.8 ± 2.1130.3 ± 2.10-1.1 ± 4.20
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 41.99Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 10.57Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 31.42Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 300 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
300 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 300 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 300 Minutes37.9 ± 2.1727.1 ± 2.16-0.1 ± 4.32
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 38.04Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 10.82Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 27.22Treatment and baseline pain categorical ratings were factors.
SecondaryPain Intensity Difference (PID) at 360 Minutes

Pain Intensity Difference (PID) from Baseline at Each Assessment Time point - pain intensity was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain with a highest possible score of 100. The pain intensity difference was calculated at each time point as the pain intensity score at baseline minus the pain intensity score at the stated time point.

Time frame:
360 Minutes
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference (PID) at 360 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Intensity Difference (PID) at 360 Minutes33.4 ± 2.1923.8 ± 2.181.0 ± 4.37
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 32.45Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.002 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 9.58Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 22.87Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 15 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
15 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 15 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 15 Minutes8.3 ± 1.099.4 ± 1.093.0 ± 2.18
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = 0.028 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 5.35Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.462 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): -1.13Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = 0.008 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 6.48Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 30 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
30 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 30 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 30 Minutes29.6 ± 1.8429.9 ± 1.834.8 ± 3.66
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 24.81Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.907 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): -0.30Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 25.11Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 45 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
45 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 45 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 45 Minutes46.1 ± 2.1044.8 ± 2.097.9 ± 4.18
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 38.19Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.655 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 1.32Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 36.87Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 60 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
60 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 60 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 60 Minutes54.4 ± 2.1650.1 ± 2.158.3 ± 4.30
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 46.15Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.155 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 4.33Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 41.82Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 75 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
75 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 75 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 75 Minutes58.0 ± 2.1852.0 ± 2.178.4 ± 4.35
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 49.69Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.05 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 6.04Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 43.65Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 90 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
90 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 90 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 90 Minutes59.9 ± 2.2253.1 ± 2.2110.1 ± 4.43
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 49.83Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.032 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 6.74Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 43.10Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 120 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
120 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 120 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 120 Minutes60.3 ± 2.2550.8 ± 2.248.0 ± 4.49
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 52.36Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.003 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 9.52Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 42.84Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 180 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
180 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 180 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 180 Minutes56.3 ± 2.3146.3 ± 2.309.5 ± 4.61
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 46.80Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.002 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 10.04Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 36.75Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 240 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
240 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 240 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 240 Minutes56.2 ± 2.4144.3 ± 2.4012.3 ± 4.81
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 43.84Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 11.82Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 32.02Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 300 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
300 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 300 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 300 Minutes52.2 ± 2.4940.5 ± 2.4813.8 ± 4.97
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 38.40Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 11.68Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 26.72Treatment and baseline pain categorical ratings were factors.
SecondaryPain Relief (PAR) Scores at 360 Minutes

Pain Relief Scores at each Assessment Timepoint - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 100

Time frame:
360 Minutes
Reported as:
Least squares mean · units on a scale
Pain Relief (PAR) Scores at 360 Minutes
units on a scaleACE-1000ACE-650ACE-0
Pain Relief (PAR) Scores at 360 Minutes48.0 ± 2.5136.6 ± 2.5014.0 ± 5.02
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 33.94Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 11.40Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 22.55Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 15 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
15 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 15 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 15 Minutes13.9 ± 1.9516.4 ± 1.944.2 ± 3.89
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = 0.027 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 9.65Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.365 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): -2.49Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = 0.005 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 12.14Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 30 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
30 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 30 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 30 Minutes50.9 ± 3.2651.3 ± 3.245.2 ± 6.50
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 45.65Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.923 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): -0.45Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 46.10Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 45 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
45 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 45 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 45 Minutes80.0 ± 3.7677.6 ± 3.748.1 ± 7.49
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 71.87Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.653 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 2.38Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 69.49Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 60 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
60 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 60 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 60 Minutes94.9 ± 3.9286.7 ± 3.908.2 ± 7.81
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 86.71Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.138 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 8.21Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 78.49Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 75 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
75 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 75 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 75 Minutes101.1 ± 4.0089.6 ± 3.997.4 ± 7.99
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 93.66Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.043 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 11.46Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 82.20Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 90 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
90 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 90 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 90 Minutes104.2 ± 4.1091.2 ± 4.089.4 ± 8.18
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 94.80Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.024 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 13.08Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 81.72Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 120 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
120 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 120 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 120 Minutes105.1 ± 4.2086.5 ± 4.185.3 ± 8.38
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 99.82Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.002 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 18.60Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 81.23Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 180 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
180 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 180 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 180 Minutes97.1 ± 4.2978.2 ± 4.276.9 ± 8.56
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 90.22Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.002 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 18.87Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 71.35Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 240 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
240 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 240 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 240 Minutes97.0 ± 4.4774.6 ± 4.4611.2 ± 8.93
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 85.82Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 22.39Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 63.44Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 300 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
300 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 300 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 300 Minutes90.1 ± 4.6267.6 ± 4.6013.7 ± 9.22
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 76.44Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 22.50Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 53.94Treatment and baseline pain categorical ratings were factors.
SecondarySum of Pain Intensity Difference and Pain Relief Scores (PRID) at 360 Minutes

Sum of PID and PAR Scores (PRID) at each Assessment Time point - pain intensity and pain relief were evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no pain and 100 = very severe pain for pain intensity and 0 = no relief and 100 = complete relief for pain relief

Time frame:
360 Minutes
Reported as:
Least squares mean · units on a scale
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 360 Minutes
units on a scaleACE-1000ACE-650ACE-0
Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 360 Minutes81.4 ± 4.6660.4 ± 4.6415.0 ± 9.31
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 66.39Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.002 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 20.98Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 45.41Treatment and baseline pain categorical ratings were factors.
SecondaryTime to Meaningful Pain Relief

Minutes until meaningful pain relief was achieved. A stopwatch was provided to the subject after ingestion of the study medication. The subject was instructed to stop the stopwatch when the relief from the starting pain was meaningful to them.

Time frame:
within 6 Hours
Reported as:
Median · Minutes
Time to Meaningful Pain Relief
MinutesACE-1000ACE-650ACE-0
Time to Meaningful Pain Relief53.7 (9.3 to 360)56.1 (15.9 to 360)NA (NA to NA)
Statistical analysis
  • ACE-1000 vs ACE-0 · Wilcoxon test, from SAS PROC LIFETEST · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the Wilcoxon test from PROC LIFETEST that compared survival curves.)
  • ACE-1000 vs ACE-650 · Wilcoxon test, from SAS PROC LIFETEST · p = 0.26 (The significance threshold level was 0.05 (two-sided). p-Values are based on the Wilcoxon test from PROC LIFETEST that compared survival curves.)
  • ACE-650 vs ACE-0 · Wilcoxon test, from SAS PROC LIFETEST · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the Wilcoxon test from PROC LIFETEST that compared survival curves.)
SecondaryTime to Confirmed Perceptible Pain Relief

Minutes until confirmed perceptible pain relief was achieved. A stopwatch was provided to the subject after ingestion of the study medication. The subject was instructed to stop the stopwatch when they first began to feel any pain relieving effect whatsoever of the drug, that was when they first felt any pain relief. It did not necessarily mean they felt completely better, although they might have, but when they first felt any difference in the pain.

Time frame:
within 6 Hours
Reported as:
Median · Minutes
Time to Confirmed Perceptible Pain Relief
MinutesACE-1000ACE-650ACE-0
Time to Confirmed Perceptible Pain Relief22.2 (3.8 to 360)22.2 (3.8 to 360)NA (NA to NA)
Statistical analysis
  • ACE-1000 vs ACE-0 · Wilcoxon test, from SAS PROC LIFETEST · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the Wilcoxon test from PROC LIFETEST that compared survival curves.)
  • ACE-1000 vs ACE-650 · Wilcoxon test, from SAS PROC LIFETEST · p = 0.934 (The significance threshold level was 0.05 (two-sided). p-Values are based on the Wilcoxon test from PROC LIFETEST that compared survival curves.)
  • ACE-650 vs ACE-0 · Wilcoxon test, from SAS PROC LIFETEST · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the Wilcoxon test from PROC LIFETEST that compared survival curves.)
SecondaryDuration of Analgesia - Time to Rescue

Minutes until rescue medication was given.

Time frame:
within 6 Hours
Reported as:
Median · Minutes
Duration of Analgesia - Time to Rescue
MinutesACE-1000ACE-650ACE-0
Duration of Analgesia - Time to RescueNA (NA to NA)NA (NA to NA)99.5 (92 to 360)
Statistical analysis
  • ACE-1000 vs ACE-0 · Log Rank · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the log-rank test from PROC LIFETEST that compared survival curves.)
  • ACE-1000 vs ACE-650 · Log Rank · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the log-rank test from PROC LIFETEST that compared survival curves.)
  • ACE-650 vs ACE-0 · Log Rank · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the log-rank test from PROC LIFETEST that compared survival curves.)
SecondaryRescue Rates Through Four Hours

Percentage of subjects using rescue medication.

Time frame:
through 4 Hours
Reported as:
Number · Percentage of Participants
Rescue Rates Through Four Hours
Percentage of ParticipantsACE-1000ACE-650ACE-0
Rescue Rates Through Four Hours20.132.480.0
Statistical analysis
  • ACE-1000 vs ACE-0 · Cochran-Mantel-Haenszel · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Odds ratio (or): 0.06Stratified by categorical baseline pain rating.
  • ACE-1000 vs ACE-650 · Cochran-Mantel-Haenszel · p = 0.002 (The significance threshold level was 0.05 (two-sided).) · Odds ratio (or): 0.52Stratified by categorical baseline pain rating.
  • ACE-650 vs ACE-0 · Cochran-Mantel-Haenszel · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Odds ratio (or): 0.12Stratified by categorical baseline pain rating.
SecondaryRescue Rates Through Six Hours

Percentage of subjects using rescue medication.

Time frame:
through 6 Hours
Reported as:
Number · Percentage of Participants
Rescue Rates Through Six Hours
Percentage of ParticipantsACE-1000ACE-650ACE-0
Rescue Rates Through Six Hours29.345.680.0
Statistical analysis
  • ACE-1000 vs ACE-0 · Cochran-Mantel-Haenszel · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Odds ratio (or): 0.10Stratified by categorical baseline pain rating.
  • ACE-1000 vs ACE-650 · Cochran-Mantel-Haenszel · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Odds ratio (or): 0.49Stratified by categorical baseline pain rating.
  • ACE-650 vs ACE-0 · Cochran-Mantel-Haenszel · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Odds ratio (or): 0.21Stratified by categorical baseline pain rating.
SecondaryPercentage of Subjects With >50% of the Maximum Possible TOTPAR6 Score

Percentage of Subjects with \>50% of the Maximum Possible TOTPAR6 Score - pain relief was evaluated using a 0-100 mm visual analog scale (VAS) where 0 = no relief and 100 = complete relief with a highest possible score of 600 so \>50% is \>300 out of 600

Time frame:
6 Hours
Reported as:
Number · Percentage of Participants
Percentage of Subjects With >50% of the Maximum Possible TOTPAR6 Score
Percentage of ParticipantsACE-1000ACE-650ACE-0
Percentage of Subjects With >50% of the Maximum Possible TOTPAR6 Score56.944.46.7
Statistical analysis
  • ACE-1000 vs ACE-0 · Cochran-Mantel-Haenszel · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Odds ratio (or): 18.45Stratified by categorical baseline pain rating.
  • ACE-1000 vs ACE-650 · Cochran-Mantel-Haenszel · p = 0.006 (The significance threshold level was 0.05 (two-sided).) · Odds ratio (or): 1.65Stratified by categorical baseline pain rating.
  • ACE-650 vs ACE-0 · Cochran-Mantel-Haenszel · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Odds ratio (or): 11.16Stratified by categorical baseline pain rating.
SecondaryPatient Global Evaluation

Patient Assessment of the Pain Medication - Number of Subjects rating the medication they received as a pain reliever on a score of 0-4, where 0=poor, 1=fair, 2=good, 3=very good, 4=excellent

Time frame:
6 Hours
Reported as:
Least squares mean · Units on a scale
Patient Global Evaluation
Units on a scaleACE-1000ACE-650ACE-0
Patient Global Evaluation2.28 ± 0.0731.95 ± 0.0730.60 ± 0.146
Statistical analysis
  • ACE-1000 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 1.68Treatment and baseline pain categorical ratings were factors.
  • ACE-1000 vs ACE-650 · ANOVA · p = 0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 0.33Treatment and baseline pain categorical ratings were factors.
  • ACE-650 vs ACE-0 · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Mean difference (final values): 1.35Treatment and baseline pain categorical ratings were factors.

Adverse events

Collected over 6 Hours (+30 days for Serious Adverse Events). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ACE-1000—0/239 (0%)45/239 (18.8%)
ACE-650—0/241 (0%)42/241 (17.4%)
ACE-0—0/60 (0%)13/60 (21.7%)
Most frequent other events
Most frequent other events
EventACE-1000ACE-650ACE-0
NauseaGastrointestinal disorders29/23926/2419/60
VomitingGastrointestinal disorders11/23911/2414/60
DizzinessNervous system disorders10/2398/2414/60

Baseline characteristics

Age Continuous
Age Continuous(years)ACE-1000ACE-650ACE-0Total
Mean18.5 ± 2.2418.3 ± 1.9618.1 ± 2.0218.4 ± 2.09
Sex: Female, Male
Sex: Female, Male(Participants)ACE-1000ACE-650ACE-0Total
Female13112031282
Male10812129258
Region of Enrollment
Region of Enrollment(participants)ACE-1000ACE-650ACE-0Total
United States23924160540
08

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
09

References and documents

Publications

  • Qi DS, May LG, Zimmerman B, Peng P, Atillasoy E, Brown JD, Cooper SA. A randomized, double-blind, placebo-controlled study of acetaminophen 1000 mg versus acetaminophen 650 mg for the treatment of postsurgical dental pain. Clin Ther. 2012 Dec;34(12):2247-2258.e3. doi: 10.1016/j.clinthera.2012.11.003. Epub 2012 Nov 28. PubMed 23200183 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2010
First posted
May 4, 2010
Start
Jun 2010
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
May 28, 2012
Last update
May 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01115673
Responsible party
Sponsor
First posted
May 4, 2010
Start date
Jun 2010
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
May 28, 2012
Last update
May 28, 2012

Study contacts

Daniel Qi, M.D.
study director · McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion